Molecular pathology of post-transplant lymphoproliferative disorders


Published: May 29, 2009
Abstract Views: 486
Untitled (): 0
PDF: 300
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Posttransplant lymphoproliferative disorders (PTLD) are a major complication of solid organ transplantation and are due to the chronic administration of iatrogenic immunosuppression.1,2 Most PTLD are of B cell origin, frequently involve extra-nodal sites, and display a marked clinical aggressiveness. Despite these common features, PTLD display histological and molecular heterogeneity and may present at different times after transplantation.1-5 Early onset (<1 year after transplantation) PTLD are mainly regarded as Epstein Barr virus (EBV)-driven lymphoproliferations that are frequently, though not always, polyclonal or oligoclonal.1-5 Conversely, most late onset (> 1 year after transplantation) PTLD are true monoclonal lymphoid malignancies that harbor EBV infection only in a fraction of cases.1-5

Supporting Agencies


Capello, D., Cerri, M., Rossi, D., Berra, E., Deambrogi, C., Franceschetti, S., Vendramin, C., De Paoli, L., Primon, V., Rus, C., Destro, T., Conconi, A., & Gaidano, G. (2009). Molecular pathology of post-transplant lymphoproliferative disorders. Hematology Meeting Reports (formerly Haematologica Reports), 1(5). https://doi.org/10.4081/hmr.v1i5.249

Downloads

Citations